Sonoran Biosciences, Inc.
Sonoran Biosciences is a privately held early stage pharmaceutical company that has developed SB Gel, a novel viscous sustained release carrier.
SB Gel enables sustained release of a wide variety of drugs to new sites in the body, including surgical sites, device surfaces, and healing tissues.
We develop new formulations using approved active ingredients, requiring reduced development cost and risk while retaining the exclusivity of a typical pharmaceutical.
Formulations based on SB Gel have potential in a number of therapeutic areas including infection, pain management, and osteoarthritis.
Our first product, SB Gel with a combination of tobramycin and vancomycin, is being developed for treatment of prosthetic joint infection.